Abbott Begins Kos Tender Offer
14th Nov 2006, 20:47 GMT
Abbott Labs said it started its previously announced cash tender offer for all outstanding shares of Kos Pharmaceuticals Last week, Abbott announced plans to buy out Kos for $3.7 bln, or $78 per share.
Abbott Begins Kos Tender Offer related news:
- Abbott Laboratories Commences Tender Offer for All Outstanding Shares of Kos Pharmaceuticals, Inc. — PR Newswire: All Releases
- Gilead Completes Tender Offer for Myogen — Operations-Related News from StratCenter.com
- Gilead Sciences Successfully Completes Tender Offer for Shares of Myogen With Over 91.3% of Shares Tendered — Operations-Related News from StratCenter.com
- Life Sciences 25 — Boston Globe -- Business News
- RealNetworks Secures 99% of WiderThan Shares; Extends Subsequent Offering Period of Tender Offer — PR Newswire: All Releases
- RealNetworks extends tender offer for WiderThan shares — bizjournals.com High Tech:Networking headlines
- Barrick Extends Offer for Pioneer and NovaGold Comments on Barrick's Decision to Waive Minimum Tender Condition — Financial News USA (OTC: FNWU)
- Kos' Swan Song — The Motley Fool
- 2007 and 2008 joint indigenous funding pool initiative tender — Vocational Education & Training Headlines
- Abbott's Humira Positive in 2 Studies — Operations-Related News from StratCenter.com
Latest news from Financial News News from StratCenter.com:
- TRADE NEWS: Agilent Technologies Introduces High-Speed, High-Volume USB Multifunction Data Acquisition Modules, Chassis
- Bio-Rad Closes Buy of Ciphergen Unit
- The LGL Group Reports Q3 Earnings
- Analogic CEO to retire
- Analogic CEO Plans to Retire
- Meade Instruments Contracts with Leading Asian Outsource Manufacturing Firm
- JMAR Receives Nasdaq Delisting Notice
- Analogic Corp Announces Mgmt Changes
- Bio-Rad Purchases Life Science Research Business From Ciphergen Biosystems
- Agilent to buy Switzerland's Acqiris